Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received a written notice (the “Notice”) from the Nasdaq Stock…


Previous articlePsychedelics Weekly – Challenging the ‘Gifting’ Part of Prop 122, Public Perception in Oregon, and The Medicine of Music
Next articlePT411 – The Humanity of Healthcare Professionals, Ancient Psychedelic Use, and Breaking the Cycle of Colonialism